Articles

Videos

Podcasts

Clinical Role

Enfortumab vedotin-efjv (Seagen; Padcev) is a first-in-class antibody-drug conjugate approved for patients with previously treated locally advanced or metastatic urothelial cancer.

Oncology Overview: Enfortumab vedotin-efjv for Advanced or Metastatic Urothelial Cancer

The prostate-specific membrane antigen-targeted positron emission tomography imaging technique will be part of the National Comprehensive Cancer Network guidelines beginning in 2022.

New Imaging Tool Could Improve Precision in Prostate Cancer Diagnoses 

Ribociclib is an inhibitor of cyclin-dependent kinase 4 and 6 and causes tumor growth inhibition.

Daily Medication Pearl: Ribociclib (Kisqali) for Breast Cancer

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses how the treatment of advanced cutaneous T cell lymphoma has changed in recent years and whether there have been any advancements of note.

How CTCL Treatment Strategies Have Changed, Advanced in Recent Years

Andrea Silber, MD, said the COVID-19 pandemic has exacerbated disparities that already existed within oncology care, and she said the effects of these disparities on patients are very real and direct.

Tackling Disparities in Oncology Requires Action, As Well As Research

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, provides an overview of key trials that have been conducted in the advanced cutaneous T cell lymphoma space in recent years.

Overview of Recent Key Trials in the CTCL Space 

Patients with triple-negative breast cancer who received sacituzumab govitecan had a median progression-free survival of 4.6 months compared to 2.3 months with chemotherapy.

Data Demonstrate Survival Benefit of Sacituzumab Govitecan In Metastatic Triple-Negative Breast Cancer Regardless of HR/HER2 Status

These patients had comparable levels of antibodies to individuals without the disease after a 2-dose course of the vaccination.

Study: COVID-19 Vaccines Provide Effective Protection for Individuals With Cancer

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explained whether the current advanced cutaneous T cell lymphoma (CTCL) treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.

Understanding the Patient Selection Process for CTCL Treatment

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, described what advanced cutaneous T cell lymphoma is in terms of classification and what current treatment approaches are available.